{"nctId":"NCT00531843","briefTitle":"The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients","startDateStruct":{"date":"2007-12"},"conditions":["Venous Thromboembolism"],"count":105,"armGroups":[{"label":"1A","type":"EXPERIMENTAL","interventionNames":["Drug: fondaparinux sodium"]},{"label":"1B","type":"ACTIVE_COMPARATOR","interventionNames":["Device: sequential compression devices"]},{"label":"2A","type":"EXPERIMENTAL","interventionNames":["Drug: fondaparinux sodium"]},{"label":"2B","type":"ACTIVE_COMPARATOR","interventionNames":["Device: sequential compression devices"]}],"interventions":[{"name":"fondaparinux sodium","otherNames":["Arixtra"]},{"name":"sequential compression devices","otherNames":["Arixtra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients age ≥ 18 years old admitted to San Francisco General Hospital for injury with at least one risk factor for venous thromboembolism (VTE).\n\nRisk factors are: Age ≥ 40 years, pelvic fracture, lower extremity fracture, spinal cord injury, shock or head injury, major operative procedure, mechanical ventilation \\> 3 days, venous injury\n\nExclusion Criteria:\n\n* prisoners\n* pregnant patients\n* patients who are anticipated to have a \\< 5 day length of stay as determined by the admitting trauma surgeon\n* patients who decline to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Normal Trough and Peak Fondaparinux Concentration","description":"Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE)","description":"Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Increased Bleeding Attributed to Fondaparinux","description":"Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":81},"commonTop":["Drop in hematocrit","DVT","Superficial nonoccluding clots"]}}}